ERBB2 and cancer: NVP‐BEZ235 and BGT226 are being used to target the PI3K pathway in various cancers.21 In addition to NRAS and PIK3CA, we identified two novel mutations in ERBB2 (p.W9fs) and PIK3R1 (p.S147* and p.L161*) (Figure S1K,L).